According to reports from Reuters, Novo Nordisk CEO Mike Doustdar announced ambitious expansion plans at the company's Capital Markets Day in London. The Danish pharmaceutical giant aims to launch more than five blockbuster drugs by 2030 and deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035. The company is targeting more than 60 million patients globally by 2030 and plans to scale up manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade. As reported by TradingView News, these ambitious plans target over 5 multi-blockbusters by 2030 with annual launches in diabetes, obesity, and other key areas. The company is also targeting revenue growth and operating margins to match industry peers, with a focus on R&D and capacity expansion to support these ambitious financial targets.
As reported by Reuters, Novo Nordisk is actively addressing market concerns about patent expirations for semaglutide, the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises. The company is racing to reassure markets that it can navigate patent expirations for semaglutide in the early 2030s. Management has detailed a multi-year rollout strategy for next-generation obesity injectables, with the CagriSema combination launching early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, before advancing zenagamtide. According to TradingView News, the company is implementing strategic resets in R&D, commercial models, and AI partnerships to drive sustainable growth and expand patient reach.
According to Reuters, shares in Novo Nordisk fell as much as 9% as analysts questioned the company's pricing power and dealmaking strategy ahead of looming patent expiries. The market reaction reflects investor concerns about the company's ability to maintain revenue streams as key patents expire in the early 2030s. As reported by TradingView News, these ambitious plans come with significant market expectations, with investors closely watching the company's execution of its multi-blockbuster strategy.
As reported by Reuters, Novo is accelerating expansion of its portfolio of pills and aims to have at least five oral assets in clinical trials before the end of this year. The company's oral Wegovy pill has achieved a record 7 million prescriptions in the US to date, with 90% of those sales flowing through direct cash-pay channels. This oral therapy expansion represents a significant diversification from the company's traditional injectable portfolio, with the company now targeting over 5 multi-blockbusters by 2030 across multiple therapeutic areas.
According to Reuters, Novo has completed significant restructuring efforts, with total departures linked to its corporate restructuring reaching 13,000 employees. This includes an initial round of 9,000 cuts and an additional 4,000 subsequent exits, reflecting the company's efforts to streamline operations and focus resources on its growth initiatives. The restructuring is part of the company's broader strategy to optimize operations while pursuing its ambitious pipeline targets.
